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Introduction  
 INTRODUCTION 
Cardiac tumours  include  benign  and  malignant  neoplasms  
arising  within  the cardiac  chambers  or  in  the  
myocardium.Approximately  70%  of  cardiac  tumours  are benign  
and  30%  are  malignant  and  potentially  capable  of  invasion  or  
metastasis1. 
Cardiac  myxomas  are  primary  cardiac  tumours  that  are 
generally  pedunculated  but  may  have  a  broad  base .They  are  
intracavitary  tumours occurring  within  any  of  the  cardiac  
chambers, but  they  have  a  predilection  for  the atria, particularly  
the  left. They  are  usually  5-6 cm  in  diameter, with  a  range  of          
1-15 cm. 
Most  atrial  myxomas, whether  left  or  right, arise  from  the 
atrial  septum , usually  from  the  region  of  limbus  of  the  fossa 
ovalis. About  10% have  other  sites  of  origin  particularly  posterior  
and  anterior  atrial  walls  and  the appendage. Most  myxomas  80%-
90%  are  in  the  left  atrium. Right  atrial  myxomas tend  to  be  
more  solid  and  sessile  than  left  atrial  myxomas,  with  a  wider 
attachment  to  the  atrial  wall  or  septum.2  Myxomas  may  
 occasionally  be  found  in right  ventricle  on  the  free  wall  or  
ventricular  septum. Few  cases  of  left  ventricular myxomas  are  
also  reported . Valvar  myxomas  arising  from  mitral, tricuspid  and 
pulmonary  valves  have  also  been  reported. 
Myxomas  may  produce  symptoms  of  hemodynamic 
derangement  from  obstruction  of  flow  within  the  cardiac  
chamber, symptoms associated  with  embolization  and  constitutional  
symptoms. 
 
HEMODYNAMIC  DERANGEMENT 
 Myxomas  may  obstruct  pulmonary  or  systemic  venous 
drainage  or  may  impair  flow  across  the  atrioventricular  valves 
.The  obstruction  is characteristically  progressive. When  obstruction  
is  intermittent , syncope, often  related to  postural  change, or  sudden  
death  may  occur. Impairment  of  valve  closure  ,either by  
obstruction  or  leaflet  damage ,may  cause  regurgitation. Although  
regurgitation  is the  dominant  abnormality  in  a  few  patients, as  a  
rule  obstruction  predominates. 
 EMBOLISM 
A  major  feature  of  cardiac  myxomas  is embolization. 
Emboli  may  arise  from  tumour  fragmentation  or  detachment  of  
entire  tumour, or from  thrombi  or  infected  foci  on  the  neoplasm. 
Systemic  emboli  occur  in  30%-45%  of  patients  with  left  atrial  
myxomas .Embolism  from  right  sided  tumours occurs  in  about  
10%  of  cases  and  may  cause  massive  fatal  pulmonary 
obstruction. Massive  pulmonary  embolism  complicating  left  atrial  
myxoma  has  been  reported 3. 
CONSTITUTIONAL  SYMPTOMS 
 In  about  30% of  patients , the  only  manifestation  of cardiac  
myxoma  are  a  plethora  of  constitutional  symptoms. Large  left  
atrial myxomas  are  particularly  apt  to  produce  constitutional  
symptoms. These  symptoms include  fever, weight  loss, clubbing, 
raynauds  phenomenon, myalgia  and arthralgia. Other  unusual  
manifestations  include  polycythemia, hemolytic  anemia. 
Nearly  all  solitary  myxomas  are non familial, myxomas  have  
familial  occurrence  in  about  5%  of  patients. Familial  myxomas  
have  autosomal  dominant  inheritance  and  are  primarily  disorders  
 of  young men. Familial  myxomas  are  associated  with  serotoli  cell  
tumour  of  testis, cushings syndrome, pituitary  tumours, centrofascial  
and  labial  lentiginosis, cutaneous  myxomas and  multiple  myxoid  
mammary  fibroadenomas. Familial  myxomas  have  the  same 
histologic  appearance  as  nonfamilial  myxomas  and  produce  the  
same symptoms, however  they  have  a  strong  tendency  to  recur. 
Investigations  to  diagnose  cardiac  myxomas  are largely  
dependent  on  Transthoracic  echo  (TTE)  supplemented by  
Transesophageal echocardiography  (TEE ) .Cardiac  catheterization  
and  angiography  no  longer constitute  the  investigation  of  choice  
unless  other types  of  cardiac  or  coronary artery  disease  require  
assessment. 
Although  rhabdomyoma  is  by  far the most  common primary  
heart  tumour  in  children  and  infancy, cardiac  myxomas are  the  
most commonly  encountered  primary  heart  tumour  in  adults. In  
this  retrospective  study we  analyse  the  incidence, presentation  and  
operative management  of  cardiac myxomas  in the  Department  of  
Cardiovascular  and  Thoracic  surgery, Madras Medical  College, 
Chennai  between  the years  2003  and  2008. 
  
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 
 REVIEW  OF  LITERATURE 
DEFINITION 
Cardiac  myxomas  are  primary  cardiac  tumours  that  are  
generally  pedenculated  but may  have  a  broad  base. Cells  are  
uniform, small  and  polygonal  with  round  or  oval nuclei  and  a  
moderate  amount  of  cytoplasm. They  lie  in  a  myxomatous  stroma  
in which  other  elements  may  be  seen. One  feature  that  distinguish  
them  from  thrombi is  that  they  are  covered  by  endothelium- lined  
crevices  and  cleft4 
 
INCIDENCE  OF  CARDIAC  MYXOMAS 
Cardiac  myxomas  comprise  29%  of  neoplasms  of  heart  
and  pericardium 5. Most myxomas  90%  are  in  the  left  atrium. 
Right  atrial  myxomas  tend  to  be  more  solid and  sessile  than  left  
atrial  myxomas  with  a  wider  attachment  to  the  atrial  wall  or 
septum6. Ventricular  myxomas  are  rare  and  are  found  to  arise  
mostly  from  right ventricular  freewall  or  ventricular  septum. In  
15%  of  reported  cases ,right ventricular  myxomas  are  associated  
 with  other  cardiac  myxomas .Left  ventricular myxomas  are  rare , 
and  little  information  is  available  about  them7 Valvar  myxomas 
arising  from  mitral, tricuspid  and  pulmonary  valves  have  been  
reported.8,9,10. 
Mcalister  and  Fenoglio  et al1  in  their  published  series  of 
tumours  of  cardiovascular  system  have  found  cardiac  myxomas  
comprised 29%, lipomas  10%, papillary  fibroelastomas  9.5%  and  
rhabdomyoma 8%  of  all  cardiac neolasms. In  the  malignant  forms  
angiomyosarcoma  predominated  with 8.8%, rhabdomyosarcoma  
with  5.8%. 
Sutsch  et al 14  in  their  published  series  of  occurrence, type 
and  location  of  cardiac  tumours  as  detected  by  Doppler  
echocardiography  are reviewed. In  their  series  of  20,305  
consecutive  echocardiographic  studies  performed at  our  institution  
over  a  four  year  period, cardiac  tumours  were  identified  in  30 
patients  (0.15%). Primary  cardiac  tumours  were  detected  in  21/30 
(70%) , secondary tumours  in 5/30 (17%) , however  in  4/30  patients  
(13%)  the  tumours  could  not  be classified. In  the  primary  tumour  
group, benign  cardiac  tumours  were  found  in 18/21  patients  
 (86%)  and  malignant  tumours  in  3/21  (14%). All  benign  cardiac 
masses  were  myxomas  (18/18)  and  accounted  for  60%  of  all  
tumours. They  were mainly  located  in  the  left  atrium 16/18  (89%)  
and  rarely  occurred  in  the  right atrium  2/18  (11%). 
 CELL  OF  ORIGIN 
Myxomas  are  composed  of  cells, primitive  capillaries  and  
foci  of  extramedullary hematopoiesis  within  a  myxoid  matrix  of  
acid  mucopolysaccharide. The  stroma contains  variable  numbers  of  
reticulocytes  and  elastin  fibres, smooth  muscle  cells and  collagen  
deposits. The  matrix  also  contains  polygonal  cells  with  scant 
eosinophilic  cytoplasm ,either  single  and  stellate  or  multinuclear  
and  in  small nests. At  the  periphery  of  the  tumour  the  cells  form  
a  monolayer  with  clustering  in  the crevices, thereby  simulating  
primitive  capillaries .The  stalk  has  abundant  large arteries  and  
veins  that  communicate  with  the  subendocardium, and  at  this 
interface, lymphocytes  and  plasma  cells  are  prominent  as  studied  
by Merkow  et al 11. 
Hurst JW  et al12  found  that the notion  that  myxomas  are  
derived from  thrombi  has  been  thoroughly  dispelled .He  found  
 that  the  nucleus  of  the polygonal  cells  are  typically  irregular  and  
slightly  hyperchromatic, but  mitosis  are not  seen. The  cells  contain  
fine  parallel  filaments  similar  to  those  seen  in  glioma and  
fibromyxosarcoma.  These  filaments  are  believed  to  be  the  
contractile components  of smooth  muscle  cells. Immunologically  
identifiable  smooth  muscle-type  filaments  are  recognized  in  
endocardial  cells, which  are  more  abundant  in  the  left  atrium, 
especially  in  the  region  of  fossa  ovalis, than  in  other  chambers. 
Ferrans  and  Roberts  et al13  in  their  study  made  that  the  
organelle content  of  myxoma  cells  does  not  provide  sufficient  
information  to  determine  the cell  of  origin .Although  myxoma  
cells  have  a  vasoformative  tendency , in  their  view  the  
cytoarchitectural  features  of  the  variously  differentiated  blood –
vessel  like structures  differ  from  those  of  normal  blood  vessels. 
Thus  myxomas  tend  to  arise from  multipotential  mesenchymal  
cells  capable  of  differentiating  into various types of  cells, a  view  
supported  by  the  finding  of bone  and  bone  marrow  tissue  in 
myxomas. Histologic  examination  of the atrial  septum  in  11  
autopsied  patients younger  than  age  4 months  revealed  
myxomatous  or  myxofibrous  tissues  in  the endocardium  near  the  
 fossa  ovalis, further  supporting  the  concept  that  myxomas  are  
derived  from  embryonal , undifferentiated  mesnchyme.   
  Vaideeswar  and  Butany  et al15  in  their  study  found  that  
cardiac myxomas arise  from  pluripotent  mesenchymal  cells  and  
are  seen  as  intracardiac, glistening  polypoid  masses  arising  from  
most  frequently  from  the  interatrial septum(IAS)  in  the  left  
atrium. They  are  composed  of  stellate  to  polygonal myxoma  cells  
in  a  mucopolysaccharide-rich  matrix. These  tumors  can  be  
sporadic or  familial. 
Basson  et al16  in  his  study  after  extensive  analysis  
ultimately confirmed  that  these  lesions  represented  a  primary  
neoplastic  process.  Although  the cell  of  origin  has  yet  to  be  
isolated,  they  have  been  posited  to  arise  from  a subendocardial  
cell,  termed  “reserve” or “lepidic” cell. These  tumors  usually  
exhibit  a  typical  hypocellular  appearance  of  small  pyramidal  or  
stellate cells  against  a bland  proteoglycan  background.  They  may  
also  exhibit  evidence  of  a  wide  variety of  cellular  lineages,  
including  zones  of  extramedullary  hematopoiesis,  acinar structures  
suggestive  of  epithelial  organization,  cells  with  electron  
 microscopic features  suggestive  of  muscle,  and  a  number  of  
immunohistochemical  markers consistent  with  a  remarkable  range  
of  cell  types.  Such  histological  studies  suggest that  the  cardiac  
reserve  cell  is  pluripotent  and,  in  the  appropriate  genetic  and 
biochemical  milieu,  may  be  a  progenitor  cell  for  a  number  of  
cardiac  cells  in  the healthy  and  pathological heart.  
Tetsuya  Kono  et al17  in  their  study  found  the  association  
between angiogenesis  and  the  clinicopathologic  features  in  cardiac  
myxoma,  vascular endothelial  growth  factor  (VEGF)  in  the  
myxoma  was  examined  by using  reverse transcriptase  polymerase  
chain  reaction  and  immunohistochemistry,  and  the  micro vessel 
density  was  determined  by  counting  micro  vessels  in  the  
myxoma  by  using immuno  staining  for  platelet  endothelial  cell  
adhesion  molecule (P-ECAM).  They found  that  there was an  
inverse  correlation  between  the  tumor  size  and  the  ratio of  the  
micro  vessel  density  in  the  central  part  to  the  micro  vessel  
density  in  the peripheral  part  of  myxoma.  Furthermore,  there  was  
an  inverse  correlation  between the  proliferating  cell  nuclear  
antigen-labeling  index  and  the  tumor  size,  and  the proliferating  
cell  nuclear  antigen-labeling  index  in  myxomas  with  high  
 vascular endothelial  growth  factors  expression  was  higher  than  
that  in  myxomas  with  low VGEF  expressions.  
 
SYMPTOMS  IN  CARDIAC  MYXOMA 
There  are  three  major  syndromes  linked  to  myxomas: 
Embolic  events, Obstruction of  blood flow  and  Constitutional  
symptoms. Embolic  events  happen  when  fragments of  the  tumour, 
or  the  thrombi  attached  to  the  outside  of  the  tumour, are  released 
and  enter  the  blood  stream .Gelatinous  myxomas  are  more  likely  
to  embolize  than the  solid form  of  this  tumour. 
Myxomas  also  may  obstruct  blood  flow  in  the  heart, 
usually  at  a  heart valve. The  mitral valve  is  the  heart  valve  most  
commonly  affected. Blood  flow restrictions  can  lead  to  pulmonary  
congestion  and  heart  valve  disease .Embolization can  lead  to  
severe  consequences. In  cases  of  left  atrial  myxomas 40-50%  of 
patients  experience  embolization. Emboli  usually  end  up  in  brain  
kidneys  and extremities. 
 The  third  syndrome  linked  to  myxomas  are  called  
constitutional syndromes, non  specific  symptoms  caused  by  the  
myxoma. 
Scott  and  Veinot  et al18  reported   their  analysis  of  clinical,  
pathologic,  and echocardiographic  features  of  cardiac  myxomas  
that  were  surgically  removed between  1976  and  1999  at  the  
university  of  Ottawa  Heart  Institute.  There  were  34 patients  
(mean age, 53 years).  Of  these  25  patients  had  symptoms,  and  the  
common symptoms  were  dyspnoea  in  13  patients  and  embolism  
in 9  patients.  Nine  patients were  asymptomatic.  
 Piazza  et al19  reported  their  experience  at  McGill  university  
teaching  hospitals, Montreal,  Quebec.  21  patients  resected  for  
primary  cardiac  tumors  were  reviewed retrospectively  in  terms  of  
clinical  presentation,  surgical  treatment,  histopathological findings  
and  outcome.  The  most  common  clinical  presentation  in  adults  
was dyspnoea  (38%),  cenral  nervous  system /embolic phenomena 
(24%),  and  in  the pediatric  age  group,  it  was  hypoxia  (50%).   
Keeling,  Oberwalder  et al20  in  their  experience  at  Karl  
Franzens  University Austria  operated  on  49  consecutive  patients  
 with  cardiac  myxoma.  In  their  series most  myxomas  originated  
from  the  left  atrium,  6.1%  from  the  mitral  valve,  4.1% from  the  
right  atrium  and  2%  had  biatrial  myxomas.  Cardiac  signs  
appeared  in 93.9%  of  the  patients  and  embolic  events  occurred  in  
26.5%.  
 Percell  et all21  in  their  study  at  Department  of  Medicine  
James  A Haley VA Hospital,  Tampa,  FL  found  that  atrial  
myxomas  are  the  most  common  primary tumor  of  the  heart  and  
occur  in  as  many  as  3  in  1000  pateints.  These  tumors  are a  
major  cause  of  patient  morbidity  and  mortality.  Approximately  
50%  of  patients with  myxomas  may  experience  symptoms  due  to  
central  or  peripheral  embolism  or intracardiac  obstruction,  but  
10%  of  patients  were  completely  asymptomatic. They were  
diagnosed  to  have  cardiac  myxomas  when  they  were  investigated  
routinely. 
MacGregor  and  Cullen  et al22  in  1959  were  the  first  to  
report  the  systemic manifestations  of  fever , weight loss,  anemia,  
increased  erythrocyte  sedimentation rate  and  elevated  globulins  in  
patients  with  cardiac  myxoma.  These  findings  are completely  
 reversible  after  removal  of  the  tumor 23. The  elevated  gamma  
globulins suggests  antibody  formation  perhaps  due  to  myxomatous  
emboli,  but  what  causes these  systemic  symptoms  is  unknown. 
 Koo Cho  et al24  in  their  experience  of  operating  20  
patients  of  cardiac myxomas  at  Severance  Hospital , Seoul  ,Korea  
95%  (19/20) of  the  patients  were symptomatic .They  had  either  
dyspnea  on  exertion ,palpitation,  paroxysmal  nocturnal  dyspnea, 
chest pain and neurological  symptoms. One  patient  was  
asymptomatic.   
 INVESTIGATIONS  FOR  DIAGNOSIS  
IMAGING  STUDIES 
Chest  Radiography 
• Abnormal  cardiac  silhouette , mimicking  mitral  stenosis 
• Unusual  intracardiac  tumour  calcification 
• Pulmonary  edema 
ECHOCARDIOGRAPHY 
Although  TEE  is  more  sensitive , 2-dimensional  
echocardiography  is  usually adequate  for  diagnosis. 
Tumour  location, size, attachment  and  mobility  can  be  
assessed  with  this technique. 
An  atrial  myxoma  must  be  differentiated  from  a  left atrial 
thrombus.The thrombus  is  usually  situated in  the  posterior  portion  
of  the  atrium  and  has  a layered  appearance. Presence  of  a  stalk  
and  mobility  favours  atrial  myxoma. 
Doppler  echocardiography  can  show  the  hemodynamic  
consequences  of  atrial myxoma. 
  
TRANS  ESOPHAGEAL  ECHOCARDIOGRAPHY 
• Better  specificity  and  100%  sensitivity  compared  to  
transthoracic echocardiography. 
• Good  resolution  of  both  atria  and  atrial  septum. 
• Better  visualization  of  anatomic  details  of  the  tumour  and  
stalk. 
• Reveals  smaller  (1-3mm)  diameter  tumours. 
• Visualizes  atrial  appendages. 
• Detects  shunting 
• Advisable  for  myxoma  syndrome-multiple  less  common  
sites. 
 
 
 
 
  
MAGNETIC  RESONANCE  IMAGING 
MRI  provides  useful  information  about  size, shape  and  
surface  charecterstics  on T1- weighted  images. Cine  MR  gradient  
echo  (GRE)  images  can  demonstrate mobility  of  the  tumour. Point  
of  attachment  is  best  visualized  by  MRI  with  a  [ost surgical  
correlation  of  83%. In  a  small  series , MRI  was  superior  to  CT  
scan ,which  showed  only  30%  correlation  for  the  site  of  
attachment. 
Information  about  tissue  composition  can  be  used  to  
differentiate  a  tumour  and  a thrombus. 
 
 
 
 
 
 
  
CARDIAC  CATHETERIZATION 
• Used  only  in  selected  patients  in  whom  non  invasive  
evaluation  is  inadequate. 
• Performed  to  exclude  coexistent  coronary  artery  disease  in  
patients  more  than  40. 
• Was  the  pre- echocardiographic  method  of  diagnosis. 
Anderson  et al25 and  Smellie  et al26  in  their  study  found  
that  those patients  with  obstructing  type  of  left  atrial  myxoma , 
their  chest  roentgenograms closely  resembles  mitral  valve  disease. 
Kerley  B  lines have  been  reported, as  has calcification  of  the  
mitral  valve. The  electrocardiogram  is  non-specific  in  left  atrial 
myxoma  and  only  reflects  the  anatomic  changes  secondary  to  the  
tumour. Atrial fibrillation  is  present  in  only  14%  of patients 27. 
Koo  Choo et al24  in  their  surgical  experience  of  20  cases  
of  atrial  myxomas  at  The  Severance  Hospital , Seoul  their  first  4  
patients  were  tested with  angiocardiography  alone,  and  3  of  these  
were  misdiagnosed.  The  last  16  were  tested  by  
 angiocardiography, M- mode  echocardiography,  and  2-dimensional 
echocardiography,  alone  or  in  various  combinations,  and  there  
were no  further misdiagnoses.  From  their  experience  they  
concluded  that  2-dimensional echocardiography  was  the  most  
accurate  method  of  diagnosing  cardiac  tumours. 
Piazza  et al19  in  their  retrospective  study  on  21  patients  
resected for  primary  cardiac  tumours,  all  but  one  of  the  tumours  
were  visualized  using transthoracic  echocardiography.  One  patient  
required  angiography  for  its  diagnosis. They  concluded  from  their  
study  that  2-dimensional  echocardiography  was  accurate in  
diagnosing  cardiac  myxomas. 
Acebo  et al28  in  their  experience  of  34  patients  25  patients  
were symptomatic, 9  were  asymptomatic. All  patients  were  
diagnosed  by  2-dimensional echocardiography  which  corroborated  
well  intraoperatively .They  concluded  that apart  from  reliability  in  
diagnosis  it  provides  additional  insight  regarding  the potential  for  
embolism.  
Agarwal  et al29  reported  their  experience  with  34  patients  
with primary  cardiac  tumours.  Of  these  31  patients  were  found  to  
 have  myxoma ,  left ventricular  fibroma  in  1, and  leiomyosarcoma  
in  2.Echocardiography  was  diagnostic in  all  the  benign  tumours,  
whereas  the  malignant  tumours  were  found  incidentally during  
surgery. 
Percell  et al21  from  their  experience  at  James A Haley VA 
Hospital  reported  that  screening  for  myxomas  should  involve  a  
thorough  history,  physical examination  and  a  transthoracic  and/or  
transesophageal  echocardiogram .Transthoracic  echocardiogram  was  
95%  sensitive  in  detecting  cardiac  myxomas, and  transesophageal  
echocardiography  approaches  100%  sensitivity.  
 
 
 
 
 
 
 
 SURGICAL  APPROACHES  FOR  CARDIAC  MYXOMAS  
Once  the  diagnosis  of  cardiac  myxoma  has  been  made,  
surgery  should  be  done  as soon  as  possible.  An  8%  mortality  
has  been  reported  in  patients  awaiting  operation  following  
definitive  diagnosis 30. Cardio-pulmonary  bypass  must  be 
established  promptly,  a  coexisting  valvular  lesion  should  be  
looked  for  and  all cardiac  chambers  and  all  main  adjacent  
cardiac  vessels  must  be  visualized  to detect  synchronous  tumors.  
Complete  cure  may  be expected,  especially  if  the involved  atrial  
septum  is  excised  and  repaired  by  patch  replacement  to  avoid 
tumor  recurrence31.   
 Piazza  et al19  in  their  series  of  21  cases  surgical  approach  
was uniatrial  in  10  patients  (48%)-seven (33%)  via  the  left atrium  
and  three (14%)  via right atrium.  Eight  patients  (38%)  required  
biatrial  approach;  the  remaining  three patients  (14%)  with  
ventricular  tumours  required  ventricular  approach.  Three  valve 
myxomas  ,two  involving  the  mitral  valve  and  one  involving  
tricuspid  valve,  were encountered;  all  underwent  conservative  
leaflet  resection  and  valve  repair.  
 Koo Choo  et al24  in  their  experience  of  20  cases  (19 cases 
of LA myxomas, 1 case of RA myxoma), all  the  LA  myxomas  were  
approached  through  the left  atrium  via  a  median  sternotomy  and  
cardio-pulmonary bypass. Before  resection, all  other  cardiac  
chambers  were  explored  for  multicentric  tumours. The  pedicle  
was then  excised  completely  along  with  a  cuff  of  tissue  to  which  
it  was  attached. The surgically  created  atrial  septal  defect  was  
closed  by  direct  suture  alone  in 10 instances,  by  prosthetic  patch  
in  8  instances  and  in  2  instance  by direct  suture  and patch  
placement. 
Baksaas  et al32  in  their  series  of  30  patients  with  cardiac  
tumours  27 patients  had  benign  tumours,  25  of  which  were  
myxomas  predominantly  located  in the  left  atrium.  All  myxomas  
were  operated  in  right  atrium  and  the  inter  atrial septum  was  
excised  with  the  myxoma  mass. All  the  other  chamber  were  
examined for  synchronous  tumour  and  the  inter  atrial  septum  was  
closed  with  patch.  
May  et al33  in  their  series  used  biatrial  approach  for  all  
cases  of  left atrial  myxoma. The  usual  incision  was  made  in  the  
 left  atrium  posterior  to  the interatrial  groove.  The  point  of  
attachment  of  the  tumour  to  the  atrium  was determined  by  
inspection  and  exploration  of  the  tumour  with  the  index  finger. 
An oblique  right  atriotomy  was  made  and  the  interior  of  the  
right  atrium  examined  in case  a  second  tumour  is  present.  The  
IAS  was  then  opened  with  a  knife  near  the center  of  the  fossa  
ovalis,  and  with  the finger  in  the  left  atrium  as  a  guide  to  the 
attachment  of  the  tumour,  a  sufficient  amount  of  atrial  septum  is  
excised  to include  the  tumour  attachment  and  if  possible  
uninvolved  tissue  5 mm  beyond  it. The  defect  in  the  IAS  was  
closed  by  direct  technique  or  with  a  pericardial  or PTFE  patch.   
The  classical  Dubost’s  technique  of  Bi-atrial  approach  is  
used  in  cases  of  large  left  atrial  myxomas  where  a  transverse  
right atriotomy  is  done  which  is  extended  onto  the  inter-atrial  
septum. Kabbani  et al 41 have  reported  24  cases  of  atrial  
myxomas  approached  through  classical  bi-atrial  approach. 
 
 
 
  
 
CONCOMITANT  VALVAR  INTERVENTIONS 
The  valves  should  be  very  thoroughly  examined  after  
removal  of  the  tumour.Concomitant  mitral  valve  procedures  may  
range  from  mitral  annuloplasty  to  valve  repairs  to  valve  
replacements. A thorough  pre-operative  diagnosis  and  intra-
operative  assessment  is  needed. Kabbani et al 41  and Semb et al 42  
have  reported  valve  replacements  in  4 cases  out  of  their  24  
reported  cases. 
 
 
 
 
 
 
  
IMMUNOLOGIC  ABNORMALITIES   IN  CARDIAC  
MYXOMA 
 
The  histologic diagnosis  is  straight  forward  ,but  the  subject  
of  discussion  concerns  the  risk  of  recurrence  after  surgery.This  
risk  has  now  been  clearly  identified   and  is  correlated  with  
young  age, a  family  history  of  myxoma  and  multifocal  lesions. 
More  recently  IL-6  and  endothelial  growth  factor  have  been  
identified  as  markers  for  these  tumours. 
 
Mendoza et al 37 38 in  their  study  have  elaborated  the  role  of  
interleukin-6  in  the  diagnosis, predicting  the  size  and  their  role  in  
detecting  recurrences. Soeparwata et al 39 in  their  study  reported  
similar  correlation  between  tumour  size  and   interleukin-6  plasma  
levels.   Selkane et al 40  in  their  series  of  40  cases  with  long  term  
follow  up  have  confirmed  the  role  of  interleukin-6  for  detecting  
recurrences.                              
 
  
 
 
 
 
 
 
 
 
Aims and Objectives  
 
  
AIMS  AND  OBJECTIVES 
Retrospective  study  to  review  and analyse the  experience  in  
diagnosis  and surgical  management with  emphasis  on  the  
evolution  at  our  institution  of  surgical techniques  and  treatment  
of  cardiac  myxomas. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Materials and Methods 
 
 MATERIAL AND METHODS 
30  consecutive  cardiac  surgical  patients  diagnosed  with  
cardiac  myxoma  admitted in  the  Department  of  Cardiovascular  
and  Thoracic Surgery , Madras  Medical College, Chennai  between  
April 1,2003  to  March 30,2008  comprised  the  sample  for this  
study .Patients  operated before  August 31,2005  were  analysed  from  
the  case sheets  obtained  from  Medical  Record  Department. A  
detailed  clinical  examination and  findings  were  recorded  over  
structured  proforma  (Annexure)  for  all  patients . 
All  the  patients  under  the  study  are  classified  according  to  
their  age,  sex , mode of  presentation , method  of  diagnosis,  site  of  
the  tumour  and  surgical  approach . 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation and Results 
  
RESULTS 
OBSERVATION  AND  RESULTS 
30  consecutive  patients  diagnosed  with  cardiac  myxoma  
who  underwent  surgical management  at  The  Department  Of  
Cadiovascular  and  Thoracic  Surgery,  Madras Medical  College, 
Chennai  between  April 1,2003 and March 31,2008  were 
retrospectively  analysed. The  subjects  chosen  in  the  study  were  
classified  into different  groups  based  on  their  age  and  sex  as  
follows  (Table 1 and 2).  
TABLE 1 
S.NO AGE TOTAL 
1 10-19 2 
2 20-29 7 
3 30-39 8 
4 40-49 10 
5 50-59 2 
6 60-69 1 
TOTAL  30 
  
 The  highest  number  of  observations  were  in  the  40-49 
years  age  group  constituting more  than  30%  of  the  study  group , 
followed  by  age  group  30-39 years (8) constituting  more  than  one  
fourth  of  the  observations. 83%  of  the  tumours  were found  to  
occur  between  20-49  years  age  group. 
TABLE- 2 
AGE MALE FEMALE TOTAL 
10-19 0 2 2 
20-29 2 5 7 
30-39 4 4 8 
40-49 2 8 10 
50-59 0 2 2 
60-69 0 1 1 
TOTAL 8 22 30 
 
Table 2  shows  that  73%  (22/30)  of  cardiac  myxoma  
occurred  in  females  and  27% (8/30)  of  the  disease  were  found  to  
occur  in  males  and  amongst  the  two  sex groups , 77%  and  100%  
of  the  disease  occurred  between  20-49  years  in  females and  
males  respectively 
 TABLE-3  
SYMPTOMS  UPON  PRESENTATION 
 
CARDIAC SYMP NEUROLOGIC 
SYMP 
CONSTITUTIONAL 
SYM 
30 2 8 
 
Table 3  shows  that  all  subjects (100%)  included  in  the  
study  presented  with  cardiac  symptoms, only 7% (2/30)  of  the  
patients  had  neurological  symptoms (one patient  had  left  
hemiparesis  and  the  other  had  Freidrich’s  ataxia), 27% (8/30)  of  
the  patients  had  constitutional  symptoms  in  the  form  of fever,  
anemia  and  raised erythrocyte  sedimentation  rate. 
 
 
 
 
 TABLE-4 
MODE  OF DIAGNOSIS 
TTE TEE CAG 
25 5 2 
 
Table 4  shows  that  Trans  Thoracic  Echocardiography  was  
diagnostic  in  25  cases (83%) ,Trans  Esophageal  Echocardiography  
was required  in  diagnosing  myxoma  in 5  cases  (17%).  2 cases  
underwent  coronary  angiogram  for  assessing  the  status  of 
coronary  arteries  preoperatively  and  were  found  to  have  normal  
coronaries. 
 TABLE -5  
SITE OF MYXOMA 
LEFT ATRIAL 21 
RIGHT ATRIAL 4 
RIGHT VENTRICULAR 2 
LEFT ATRIAL AND MV 2 
MITRAL VALVE 1 
TOTAL 30 
 
Table 5  shows  the  location  of  cadiac  myxomas  in  the  
cases  included  in  the study. Myxomas  were  found  in  the  left  
atrium  in  21/30  cases  (70%), Right  atrial myxomas  were  found  in  
13%  of  cases.2  cases  (7%)  had  Right  ventricular myxomas. One  
case  was  found  to  have  isolated  mitral  valve  myxoma  involving  
the  posterior  mitral  leaflet  and  another  two  cases  involving  the  
left  atrium  and mitral  valve. 
 TABLE-6 
SITE  OF  PEDICLE  ATTACHMENT  TO  ATRIAL  WALL 
LEFT ATRIAL SEPTUM INV. 
F.O 
18 
LEFT ATRIAL SEPTUM NOT 
INV F.O 
05 
FOSSA OVALIS IN RT.ATRIUM 04 
MITRAL VALVE PML 01 
TREBACULAR SEPTUM IN RV 01 
RIGHT VENTRICULAR WALL 01 
 TOTAL 30 
 
The  sites  to  which  the  stalks  of  the  atrial  myxomas  were  
attached  are  summarized in  Table 6. Most  commonly  the  
attachment  was  to  the  fossa ovalis  ,and  with  one exception  
(attachment to the Poterior mitral leaflet ), the  other  neoplasms  also  
involved  the  interatrial  septum. Diameters  of  the  atrial myxomas  
measured  laterally and  discounting  pedicles, ranged  from  2cm  to  
8cm. There  were  two  right ventricular  myxomas  each  involving  
the  trebacular  septum  and  right  ventricular  free  wall. 
 TABLE -7 
SURGICAL APPROACH AND TECHNIQUES 
RIGHT ATRIAL 25 
BI-ATRIAL 03 
LEFT ATRIAL 01 
RIGHT VENTRICULAR 01 
  TOTAL 30 
 
Table 7 shows  the  surgical  approach  used  for  myxoma  
excision. Majority  of  the cases  (83%)  were  removed  by right  atrial  
approach  (25/30)  cases.  Bi-atrial  technique  was  used  for  tumour  
excision  in  3  cases, Left  atriotomy  was  done  in  1 case  (removal  
of  tumour  arising  from  PML  of  MV). Right ventriculotomy  was 
done  for  tumour  retrieval  in  a  case  of  RV  myxoma. 
 TABLE -8 
MEAN ACC TIME AND CPB TIME 
S.NO APPROACH ACC  
TIME(MEAN) 
CPB 
TIME(MEAN) 
1 RT.ATRIAL 49.96’ 86.76’ 
2 BI-ATRIAL 100.6’ 153.0’ 
3 LEFT ATRIAL 108.0’ 148.0’ 
4 RIGHT VENTR 66’ 124’ 
 
Table 8 shows the  mean  Aortic  cross  clamp  time  and  Total  
cardiopulmonary bypass  time  recorded  for  each  approach  .Short  
cross  clamp  time  and cardiopulmonary  bypass  time  were  noted  in  
right  atrial  approach. 
In  all  30  cases  ,the  atrial  myxomas  were  excised  through  
a  median sternotomy, cardiopulmonary  bypass. In  all  cases , cardiac  
arrest  was  achieved  with  antegrade cold  crystalloid  cardioplegia  
with  topical  hypothermia. Typically  a  right  atrial incision  was  
 made  paralle l to  right  atrioventricular  groove  in  25 cases. The  
superior portion  of  the  inter-atrial  septum  was  incised  to  visualize  
the  left  atrial  mass .Once the  tumour  was  visualized  from  the  
right  atrial  aspect, the  rest  of  the  atrial  septum was  incised  
carefully  avoiding  cutting  through  the  left  atrial  mass .Before 
resecting the  other  chambers  were  explored  for the  occasional  
multicentric tumour. The pedicle  was  completely  excised  along  
with  a  cuff  of  tissue  to  which  it  was attached. To  minimize  the  
risk  of  embolization , great  care  was  taken  to  handle  the pedicle  
gently ,and  to  remove  any  residual  tumour  debris  from  the  
surgical  field. 
 The  surgically  created  septal  defect  was  closed  by  the  
following methods:  in  22  instances , by  pericardial  patch  closure  
with running monofilament suture. In  3  instances  by  direct  closure. 
 Two  patients  required  mitral valve replacement in  addition  to  
myxoma  excision .One  patient  required  mitral valve repair  in 
addition  to  myxoma  excision. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 DISCUSSION 
 
PREVALENCE 
 Primary  cardiac  tumours  are  rare  ,and  80%  of  them  are  
benign. They  account  for 5%  to  10%  of  all  cardiac  neoplasms, 
the  balance  of  which  are  secondary  tumours (therefore  metastatic  
and  malignant).Myxomas  account  for  approximately  50%  of  all  
primary  cardiac  neoplasms ,and  have  been  reported  in  all cardiac 
chambers. Although  about  75% of  myxomas  occur  in  the  left 
atrium  and  25%  in  the  right 34, multiple  myxomas  have  been  
reported  in  5%  of  patients  with  left  atrial  or  left ventricular  
myxomas. Myxomas  predominantly  occur  in  women  in  the  3rd to 
6th decades  of  life,  and familial  tendency  have  been  reported 35.In  
 our  experience myxomas  were  found  to  occur  predominantly  
between  20-49  years  age  group (83%)  as  shown  in  Table -1. The  
tumour  was  found  to  occur  predominantly  in females  in  73%  and  
males  in  27%, however  in  both  sex  groups  the  tumour occurred  
mostly  between  20 -49  years  as  shown  in  Table-2. 
 
CLINICAL  MANIFESTATIONS 
Although  small  tumours  may  be  asymptomatic ,the  clinical  
manifestations of  atrial  myxomas ,when  they  occur  are  well  
recognized. The  most  common findings  are  symptoms  of  valvular  
obstruction  and  signs of  peripheral embolization. In  our  study  
group  all  patients  30/30 (100%) presented  with  any  one  of  the 
cardiac  symptoms  in  the  form  of  dyspnea  on  exertion, palpitation, 
paroxysmal nocturnal  dyspnea, chest  pain  and  discomfort. This  is  
 attributed  to  the  fact  that most  cases  seek  medical  attention  only  
when  they  become  symptomatic  and screening  for  such  cases  are  
far  from  their  reach. We  encountered  1  case  of  atrial myxoma  
with  systemic  embolization  and  one  case  was  associated  with  
Freidrich’s Ataxia.  Constitutional  symptoms such  as  fever, weight 
loss,  arthralgia  and  anemia were  noted  in  27%  of  the  cases  
(8/30)  in  ou r study  as  shown  in  (Table-3). 
 Although  the exact  incidence  of  chamber  enlargement  in  
chest roentgenography  in  patients  with  cardiac myxoma  has  not  
been  described, chamber enlargement/hypertrophy  was  found  to  
occur  in  47% (14/30)  of  cases  in  our  study. 
 
 
 
 DIAGNOSIS  
Historically  cardiac  tumours  have  been  diagnosed  by  
angiocardiography  and  M-mode  echocardiography. Transseptal  
angiocardiography  has  been  used  in  in numerous  centers, but  
tumour  embolism  has  been  reported  with  use of  this  method 36. 
Pulmonary  levophase  angiocardiography  has  proved  a  reasonably  
accurate method  of  visualizing  a  left  atrial  myxoma. Yet  in  our  
series, cardiac  catheterization  was  not  used  as  the  sole  
radiological  method  of  diagnosing  a myxoma ,however 2 cases  
underwent catheterization  for  assessing  their  coronary artery  status  
preoperatively. 
In  25  of  our  patients, the  cardiac  mass  was  diagnosed  
preoperatively by  Trans  Thoracic  Echocardiography. 5  patients with  
left  atrial  myxoma  required Trans  Esophageal  Echocardiography  
 for  the  confirmation .In  our  study 2-dimensional  echocardiography  
was  diagnostic  in  83%  of  cases  and  TEE  was needed  for  
confirmation  in  rest  of  the  cases  Surgical  findings  corroborated  
with the  echocardiographic  findings  in  all  but  one  case  where  
mxyoma  was  found  to  be  adherent  extensively  to  roof  of  left 
atrium, mitral  valve  and  inter-atrial  septum as  shown in  Table-6. 
 
 SURGICAL  OBSERVATIONS  AND  RECOMMENDATIONS 
 When  a  diagnosis  of  left atrial  myxoma  is  made, surgery  
should  be done  without  delay .Current  surgical  techniques for 
treating  atrial  myxomas  include median  sternotomy  with  total  
cardiopulmonary  bypass ,using  moderate  hypothermia with  cold  
crystalloid  cardioplegia  with  minimal  touch  technique  of  the  
 heart  to prevent  tumour  embolization,  which  can  be  a  serious  
intraoperative  complication  of  this  procedure. 
 Standard  surgical  approach  for  the  management  of  left  
atrial  myxoma  is  Bi-atrial ,but  in  our  experience  in  the  
management  of  30  cases, we  used  Right  atrial approach  alone  for 
the  management  of  25  cases  of  cardiac  myxomas. Of  the  21 
cases  of  isolated  left  atrial  myxoma  without  involving  mitral  
valve,  20 cases  were approached  through  right  atrium  and  one  
case  was  approached  through  left atrium. All  the  four  cases  of  
Right  atrial  myxoma  were  operated  through  right  atrium. Of the  
two  right  ventricular  myxomas,  one  was  removed  through  right  
atrium  and  the other  required  a  right  ventriculotomy  as  shown  in  
Table-7. Bi-atrial  approach  was used  in 3  cases  were  tumour  was  
hugely  enlarged  and  adherent  to  mitral valve. The  mean  Aortic  
 cross  clamp  time  and  Cardiopulmonary  bypass  time was  shorter in  
patients  operated  through  right atrium  compared  to  patients  who  
were  operated through  Bi-atrial  and  left atrial  approach  as  shown  
in  table 8.  All  cases  included  in the  study  were  discharged  and 
no  deaths  have occurred.  From  our  study  right  atrial approach  as  
an  alternative to  Bi-atrial  approach  in  the  management  of  cardiac 
myxomas  arising  from  left  atrium  is  worth  mentioning. 
  
 
 
 
PHOTOGRAPH SHOWING INTRAOPERATIVE TUMOUR 
REMOVAL THROUGH RIGHT ATRIAL APPROACH. 
 
 
  
 
 
 
 
PHOTOGRAPH SHOWING 3x3 CM LEFT ATRIAL 
MYXOMA MASS OF A PATIENT 
  
 
 
 
HISTOPATHOLOGICAL  PHOTOGRAPH  OF  CARDIAC  
MYXOMA 
  
 
 
 
OPERATIVE  PHOTOGRAPH  SHOWING  A  RIGHT  
VENTRICULAR  MYXOMA  VISUALISED  THROUGH  
THE  RIGHT  ATRIUM
  
 
 
 
PHOTOGRAPH  SHOWING  RIGHT  VENTRICULAR  
MYXOMA  EXCISED  THROUGH  RIGHT  ATRIUM
  
 
 
 
PHOTOGRAPH  SHOWING  LEFT  ATRIAL  MYXOMA  
EXCISED  THROUGH  RIGHT  ATRIUM
  
 
 
 
PHOTOGRAPH  SHOWING  THE  INTER-ATRIAL  
SEPTUM  CLOSED  WITH  PERICARDIAL  PATCH
  
 
  
 
PHOTOGRAPH  SHOWING  SPECIMEN  TUMOUR  OF  
RIGHT  VENTRICULAR  MYXOMA
  
 
 
 
HISTOPATHOLOGICAL  PHOTOGRAPH  OF  CARDIAC  
MYXOMA
  
 
 
HISTOPATHOLOGICAL  DEMONSTRATION  OF  
MYXOMA  CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary and Conclusions 
 SUMMARY  AND  CONCLUSIONS 
A  retrospective  analysis  of  30  consecutive  cases  of  Intra  
cardiac  myxomas  were analysed  according  to  their  age,  sex , 
mode  of  presentation,  method  of  diagnosis, site  of  the  tumour  
and  surgical  approach. The  surveyed  cases  showed  nearly  73% 
and  27%  of  myxomas  occurred  in  females  and  males  
respectively. Distribution  of myxomas  by  age  indicated nearly  83%  
of  cases  occurred  between  20-49 years  age group. This  data  also  
illustrated  that  100% males  and  77%  females  harboured  the 
disease  between  20-49 years. All  the cases  included  in  the  study  
(100%)  presented with  cardiac  symptoms  which  warranted  them  
for  medical  attention. However  a systematic  screening  is  
essentially  required  to  diagnose  and  treat  cases  at asymptomatic  
 level  with  a  view  to  prevent  morbidity. 7%  of  the  cases  included  
in the  study  presented  with  neurological  symptoms, 27%  cases  
had  constitutional symptoms. Trans  thoracic  echocardiography  was  
diagnostic  in  83%  of  the cases. However,  Trans  esophageal  
echocardiography  was  needed  for  confirmation  in  the rest  of  the  
cases (17%) .Angiocardiography  as  a  mode  of  investigation  in  the 
diagnosis  was  not  required  in  our  study. In  our  observation  80%  
(24 cases)  of  the tumours  occurred  in  left  atrium  of  which  21  
cases  (70%)  involved  the  inter atrial septum, 2  cases  involved  the  
left atrium  and  mitral  valve  and  1  case  was  diagnosed  to  have  
mitral  valve  myxoma. 13%  of  the  cases  were  found  in  the  right 
atrium  and  7%  cases  were  observed  in  the  right  ventricle. The  
fossa  ovalis was the  site  of  pedicle  attachment  in  73%  of  the  
cases. Right  atrial  approach  was  used in  83%  of  the  cases  for  
 tumour  excision , Bi-atrial  approach  was  needed  in  10% ,left  atrial  
and  right  ventricular  approach  was  needed  in  1  case  each.  The  
mean cross  clamp  time  and  total  cardiopulmonary  bypass  time  
was  shorter  when  right atrial  approach  was  employed  for  tumour  
excision  as  compared  to  classical  bi-atrial  approach.  Hence  we  
conclude  that  cardiac  myxomas  are  a  rare  group  of tumours  and  
cardiovascular  surgeons  must  be  familiar  with  this  condition  as  
only  a  tip  of  an  iceberg  present  to  us, right  atrial  approach  could  
be  used  as  an alternative  to  the  classical  bi-atrial  approach.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Proforma 
 
 PROFORMA 
¾ ANNEXURE 1 
¾ PATIENT NAME:  AGE/SEX: 
¾ MRD NO: 
¾ ADDRESS: OCCUPATION: 
¾ CONSULTANT IN-CHARGE: UNIT: 
¾ DATE OF ADMISSION: 
¾ DATE OF SURGERY: 
¾ DATE OF DISCHARGE: 
¾ CHIEF COMPLAINTS: 
¾ CARDIAC SYMPTOMS:DYSPNEA /PALPITATIONS/ PND/ 
CHESTPAIN/ PEDAL EDEMA. 
¾ NEUROLOGIC SYMPTOMS: 
¾ CONSTITUTIONAL SYMPTOMS:FEVER/ WEIGHT LOSS/ 
ARTHRALGIA/ 
¾ PAST HISTORY: FAMILY H/O  
¾ GENERAL EXAMINATION: 
 ¾ PALLOR  +/- 
¾ CYANOSIS +/- 
¾ JAUNDICE  +/- 
¾ CLUBBING +/- 
¾ PEDAL EDEMA +/- 
¾ PR: 
¾ BP: 
¾ SYSTEMIC EXAMINATION: 
¾ CARDIOVASCULAR SYSTEM: 
¾ RESPIRATORY SYSTEM: 
¾ NEUROLOGICAL EXAMINATION: 
¾ INVESTIGATIONS: 
¾ Hb: PCV: ESR: 
¾ ECG: 
¾ CHEST X-RAY: 
¾ TRANS-THORACIC ECHOCARDIOGRAPHY: 
¾ TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY: 
 ¾ CORONARY ANGIOGRAPHY: 
¾ DIAGNOSIS: 
¾ SURGICAL PROCEDURE: 
¾ APPROACH:  RT ATRIAL/BI-ATRIAL/LEFT ATRIAL 
¾ TUMOUR LOCATION/SIZE: 
¾ SITE OF ATTACHMENT OF PEDICLE: 
¾ CLOSURE OF IAS DEFECT: 
¾ CROSS CLAMP TIME: 
¾ TOTAL CPB TIME: 
¾ OUTCOME: 
¾ BIOPSY REPORT: 
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 NAME AGE SEX IP NO DIAGNOSIS  CS NSS ESR CXR ECHO CAG APPROACH  SIZE SITE OF PEDICLE IAS CL ACC CPB OUTCOME BX 
KRISHNAN 42  M 611620 LA MYXOMA    +    --   N N D NO RA  5x5 IAS/FO PPC 54' 98' DIS PROVEN 
MEHRUNISHA 35 F 613505 RV MYXOMA    +    --   E RA/RV EN D NO RV  4x4 TR.SEPTUM    ---- 66' 122' DIS PROVEN 
SHANTI 43 F 629835 LA MYXOMA    +    +   N LAE D NO RA  4x4 IAS/FO PPC 52' 96' DIS PROVEN 
MANI 35 M 622978 LA MYXOMA    +    --    N LAE D NO RA  3x3 IAS PPC 56' 105' DIS PROVEN 
PONNAMAL 22 F 634534 LA MYXOMA    +    +   N N D NO RA  2x2 IAS/FO DC 34' 52' DIS PROVEN 
PADMA 42 F 662935 LA MYXOMA    +    +   N LAE D NO RA  4x4 IAS PPC 62' 126' DIS PROVEN 
BRINDA 13 F 656416 LA MYXOMA    +    +   E  LAE D NO RA  7x5 IAS/FO PPC 58' 128' DIS PROVEN 
 KUPPAMAL 40 F 632098 LA MYXOMA    +    --   N N D NO BI-ATRIAL  4x4 IAS/FO PPC 72' 144' DIS PROVEN 
REVATHY 25 F 701329 LA MYXOMA-MR    +   +   N CM D NO BI-ATRIAL  5x5 AML/PML/LAROOF MVR/PPC 112, 156' DIS PROVEN 
PRABHA 30 F 722189 LA MYXOMA    +   --   N N D NO RA  3x2 IAS/FO PPC 48' 92' DIS PROVEN 
CHELAMAL 40 F 696320 LA MYXOMA    +   --   E N D NO RA  3x2 IAS/FO PPC 50' 98' DIS PROVEN 
DAYALAN 33 M 708292 LA MYXOMA 
   -
MR    +   +   N LAE D NO BI-ATRIAL  8x5 IAS/ANT.CUSP/COR MVREP/PPC 118' 160' DIS PROVEN 
MARIAMA 28 F 712683 RA MYXOMA    +   --   E N D NO RA  3x3 IAS/FO PPC 38' 54' DIS PROVEN 
KRISHNAN 30 M 708828 RA MYXOMA    +   --   E N D NO RA  3x2 IAS/FO PPC 36' 54' DIS PROVEN 
 NAVAMANI 36 F 709473 LA MYXOMA    +   --   N N D NO RA  4x3 IAS/FO PPC 40' 60' DIS PROVEN 
KULLAN 36 M 572350 LA MYXOMA    +   --   N N D NO RA  4x4 IAS/FO PPC 42' 58' DIS PROVEN 
BEEMASWAMY 45 M 808679 LA MYXOMA    +   -- N N D/TEE NO RA  2x2 IAS/FO DC 32' 50' DIS PROVEN 
PITCHAMAL 58 F 820422 LA MYXOMA    +   -- N N D  N RA  3x3 IAS/FO PPC 44' 96' DIS PROVEN 
MANI 45 F 841824 RA MYXOMA    +   -- N N D NO RA  6x6 IAS/FO PPC 55' 100' DIS PROVEN 
PONNI 42 F 843278 LA MYXOMA    +   -- N N D/TEE NO RA  4x3 IAS/FO PPC 56' 106' DIS PROVEN 
VALLI 27 F 854432 LA MYXOMA    +   --    E LAE D/TEE NO RA  5x5 IAS/FO   PPC 64' 124' DIS PROVEN 
MUNIAMAL 53 F 827229 LA MYXOMA    +   -- N LAE D   N RA  5x5 IAS/FO PPC 58' 114' DIS PROVEN 
 SARAVANAN 20 M 774827 MYXOMA MV    +   +  E LAE D NO LA  6x6 PML MVR 108' 148' DIS PROVEN 
GAJENDRAN 26 M 5909 RV MYXOMA    +   -- N RAE D NO RA  4x4 RV WALL  ---- 62' 134' DIS PROVEN 
SELVI 20 F 27968 LA MYXOMA    +  --   E LAE D/TEE NO RA  5x5 IAS/FO PPC 68' 126' DIS PROVEN 
SUNDARI 43 F 72380 LA MYXOMA    +   --   N LAE D NO RA  4x4 IAS/FO PPC 52' 118' DIS PROVEN 
AMMU 32 F 66553 LA MYXOMA    +  --  N  N D NO RA  3x3 IAS/FO PPC 40' 64' DIS PROVEN 
PAPPA 60 F 81543 RA MYXOMA    +  --  N  RAE D NO RA  4x4 IAS/FO PPC 54' 116' DIS PROVEN 
DHANALAXMI 40 F 13203 LA MYXOMA    +   +   N  N D/TEE NO RA  4x4 IAS PPC 58' 94' DIS PROVEN 
MEENA 18 F 773241 LA MYXOMA    +   --   N  N D NO RA  2x2 IAS/FO DC 36' 58' DIS PROVEN 
 APPENDIX  2 
¾ KEY TO MASTER CHART 
¾ RA: RIGHT ATRIAL 
¾ LA: LEFT  ATRIAL 
¾ RV: RIGHT VENTRICLE 
¾ LAE: LEFT ATRIAL ENLARGEMENT 
¾ RAE: RIGHT ATRIAL ENLARGEMENT 
¾ CM: CARDIOMEGALY 
¾ IAS:  INTER ATRIAL SEPTUM 
¾ FO: FOSSA OVALIS 
¾ AML:  ANTERIOR MITRAL LEAFLET 
¾ PML:  POSTERIOR MITRAL LEAFLET 
¾ PPC: PERICARDIAL PATCH CLOSURE 
¾ DC: DIRECT CLOSURE 
¾ CAG:  CORONARY ANGIOGRAM 
¾ MVR: MITRAL VALVE REPLACEMENT  
¾ ACC:  AORTIC CROSS CLAMP TIME 
¾ CPB: CARDIO-PULMONARY BYPASS 
  
